Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tideglusib in congenital and juvenile-onset myotonic dystrophy type 1
NCT02858908Phase 2Completed
- Sponsor
- AMO Pharma Limited
- Start
- Jul 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tideglusib in myotonic dystrophy type 1 (DM1), sponsored by AMO Pharma Limited. Started Jul 2016; status: completed.
02
Drugs
tideglusib
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT02858908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02858908.